Reversible posterior leukoencephalopathy syndrome: diagnosis and management in the setting of lung transplantation
Reversible posterior leukoencephalopathy syndrome (RPLS) is a potentially devastating early complication of calcineurin inhibitor (CNI) therapy in solid organ transplantation. Management centres on cessation of CNI therapy; however, this strategy is complicated in lung transplantation because of the threat of allograft rejection, or, if CNI is replaced with mammalian target of rapamycin‐based immunosuppression, poor wound healing and bronchial dehiscence. We describe four cases of RPLS after lung transplantation, emphasizing the diagnostic and management approach required to maintain a healthy allograft and ensure that RPLS is, as the name suggests, reversible.
No Supplementary Data
No Article Media
Document Type: Research Article
Affiliations: Queensland Centre for Pulmonary Transplantation and Vascular Disease, the Prince Charles Hospital, Brisbane, Queensland, Australia
Publication date: 2010-10-01